Not Yet Recruiting OBSERVATIONAL NCT06298292

Acceptability/Tolerance of Protein Substitutes in Tablet Form for the Dietary Management of Rare Aminoacidopathies (ZeroMinisMR)

Zero Minis - Acceptability and Tolerance Market Research

Sponsor: Birmingham Women's and Children's NHS Foundation Trust

Conditions Alkaptonuria Homocystine; Metabolic Disorder MSUD (Maple Syrup Urine Disease) Tyrosinemia, Type I Tyrosinemia, Type II Tyrosinemia, Type III

Interventions Zero minis (range of protein substitutes in tablet form)

Updated 3 times since 2024 Last updated: Mar 1, 2024 Started: Apr 1, 2024 Primary completion: Mar 31, 2026 Completion: Jun 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06298292, this observational or N/A phase trial focuses on Alkaptonuria and Homocystine; Metabolic Disorder and remains actively recruiting participants. Sponsored by Birmingham Women's and Children's NHS Foundation Trust, it has been updated 3 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting
Apr 2024 — Jul 2024 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Birmingham Women's and Children's NHS Foundation Trust
Great Ormond Street Hospital for Children NHS Foundation Trust
metaX Institut fuer Diatetik GmbH

Data source: metaX Institut fuer Diatetik GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.